Bluefin Biomedicine

Ownership

Private

Therapeutic Areas

Oncology

Stage

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Modalities

Antibody-based therapeutics

Bluefin Biomedicine General Information

Bluefin Biomedicine is developing antibody-based treatments for orphan cancer indications, focusing on underserved patients. The company uses proprietary proteomics, transcriptomics, and bioinformatics methods to study cancer tumors and identify differentially expressed cancer antigens for therapeutic antibody development.

Contact Information

Website

https://www.bluefinbiomed.com/

Primary Industry

Biotech

Corporate Office

Beverly, Massachusetts
United States

Drug Pipeline

No pipeline data available

For full access to Bluefin Biomedicine's pipeline data

Book a demo

Key Partnerships

No partnerships listed

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Bluefin Biomedicine Funding

No funding data available

Early Stage VC (Series A)	04-Jun-2020	$38M	Completed	Phase 1
Seed Round	12-Feb-2019	$8.5M	Completed	Startup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more

To view Bluefin Biomedicine's complete valuation and funding history, request access »